Invivyd (IVVD) Cash from Operations (2021 - 2025)
Invivyd's (IVVD) quarterly Cash from Operations came in at -$15.5 million in Q4 2025, up 58.91% on a YoY basis from -$9.7 million in Q4 2024, and down 87.33% quarter-over-quarter from -$8.2 million in Q3 2025.
Analysis
Invivyd (IVVD) Cash from Operations (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has reported Cash from Operations for 5 consecutive years, with -$15.5 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations rose 58.91% year-over-year to -$15.5 million; the trailing twelve-month figure through Dec 2025 stood at -$58.1 million (up 65.9% YoY), and the FY2025 full-year result was -$58.1 million, up 65.9% from the prior year.
- Cash from Operations fell to -$15.5 million in Q4 2025 per IVVD's latest filing, from -$8.2 million in the prior quarter.
- Across five years, Cash from Operations topped out at -$8.2 million in Q3 2025 and bottomed at -$73.2 million in Q4 2021.
- Historically, Cash from Operations has averaged -$40.3 million across 5 years, with a median of -$41.1 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations sank 148.72% in 2022, then soared 79.91% in 2025.
- Over 5 years, Cash from Operations stood at -$73.2 million in 2021, then surged by 35.25% to -$47.4 million in 2022, then slipped by 24.97% to -$59.2 million in 2023, then soared by 36.51% to -$37.6 million in 2024, then soared by 58.91% to -$15.5 million in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered -$15.5 million, -$8.2 million, and -$13.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 4.00 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 3.57 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.13 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 813.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -526.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 448.90 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -15.46 Mn |
| Sep 30, 2025 | -8.25 Mn |
| Jun 30, 2025 | -13.30 Mn |
| Mar 31, 2025 | -21.13 Mn |
| Dec 31, 2024 | -37.61 Mn |
| Sep 30, 2024 | -41.07 Mn |
| Jun 30, 2024 | -41.60 Mn |
| Mar 31, 2024 | -50.21 Mn |
| Dec 31, 2023 | -59.24 Mn |
| Sep 30, 2023 | -35.35 Mn |
| Jun 30, 2023 | -37.39 Mn |
| Mar 31, 2023 | -41.18 Mn |
| Dec 31, 2022 | -47.40 Mn |
| Sep 30, 2022 | -56.14 Mn |
| Jun 30, 2022 | -57.39 Mn |
| Mar 31, 2022 | -59.05 Mn |
| Dec 31, 2021 | -73.21 Mn |
| Sep 30, 2021 | -54.21 Mn |
| Jun 30, 2021 | -33.57 Mn |
| Mar 31, 2021 | -23.74 Mn |